Mylan (MYL) stock price, revenue, and financials
Mylan market cap is $8.6 b, and annual revenue was $11.5 b in FY 2019
$15.855
$8.6 B
MYL Mkt cap, 28-Jan-2021$3 B
Mylan Revenue Q3, 2020Mylan Gross profit (Q3, 2020)1.2 B
Mylan Gross profit margin (Q3, 2020), %39%
Mylan Net income (Q3, 2020)185.7 M
Mylan EBIT (Q3, 2020)351.4 M
Mylan Cash, 30-Sept-2020664.5 M
Mylan EV20.3 B
Mylan Revenue
Mylan revenue was $11.5 b in FY, 2019 which is a 0.6% year over year increase from the previous period.
Mylan Revenue Breakdown
Mylan revenue breakdown by business segment: 16.0% from Central Nervous System & Anesthesia, 14.5% from Infectious Disease, 15.9% from Respiratory & Allergy, 7.8% from Cardiovascular, 10.0% from Gastroenterology, 7.3% from Diabetes & Metabolism, 6.3% from Women’s Health, 9.2% from Oncology and 13.0% from Other
Mylan revenue breakdown by geographic segment: 27.9% from Rest of World, 36.6% from North America and 35.5% from Europe
Mylan Income Statement
Annual
| USD | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|
Revenue | 11.9b | 11.4b | 11.5b |
Revenue growth, % | (4%) | 1% | |
Cost of goods sold | 7.1b | 7.4b | 7.6b |
Gross profit | 4.8b | 4.0b | 3.9b |
Gross profit Margin, % | 40% | 35% | 34% |
R&D expense | 783.3m | 704.5m | 639.9m |
General and administrative expense | 2.6b | 2.4b | 2.6b |
Operating expense total | 3.3b | 3.1b | 3.2b |
EBIT | 1.4b | 905.6m | 715.5m |
EBIT margin, % | 12% | 8% | 6% |
Interest expense | 534.6m | 542.3m | 517.3m |
Pre tax profit | 903.0m | 298.4m | 154.4m |
Income tax expense | 207.0m | (54.1m) | 137.6m |
Net Income | 696.0m | 352.5m | 16.8m |
EPS | 1.3 | 0.7 | 0.0 |
Quarterly
| USD | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 2.7b | 2.8b | 2.9b | 2.5b | 2.9b | 3.0b | 2.6b | 2.7b | 3.0b |
Cost of goods sold | 1.7b | 1.8b | 1.8b | 1.7b | 1.9b | 1.9b | 1.7b | 1.7b | 1.8b |
Gross profit | 984.3m | 962.5m | 1.0b | 805.2m | 932.6m | 1.1b | 906.1m | 1.0b | 1.2b |
Gross profit Margin, % | 37% | 34% | 36% | 32% | 33% | 36% | 35% | 38% | 39% |
R&D expense | 204.9m | 206.7m | 144.1m | 172.6m | 147.6m | 167.9m | 114.2m | 156.3m | 129.8m |
General and administrative expense | 607.5m | 623.3m | 577.3m | 607.9m | 668.6m | 632.7m | 605.4m | 719.4m | 658.4m |
Operating expense total | 828.6m | 783.6m | 701.0m | 781.2m | 837.1m | 748.7m | 721.4m | 891.5m | 807.1m |
EBIT | 155.7m | 178.9m | 338.2m | 24.0m | 95.5m | 323.7m | 184.7m | 134.2m | 351.4m |
EBIT margin, % | 6% | 6% | 12% | 1% | 3% | 11% | 7% | 5% | 12% |
Interest expense | 131.7m | 139.2m | 136.2m | 131.2m | 131.2m | 128.9m | 119.9m | 116.2m | 117.3m |
Pre tax profit | 10.5m | 18.7m | 192.2m | (114.5m) | (52.1m) | 185.8m | 30.7m | 20.0m | 241.6m |
Income tax expense | (76.6m) | (18.8m) | 15.5m | (89.5m) | 116.4m | (4.0m) | 9.9m | (19.4m) | 55.9m |
Net Income | 87.1m | 37.5m | 176.7m | (25.0m) | (168.5m) | 189.8m | 20.8m | 39.4m | 185.7m |
EPS | (0.2) | 0.1 | 0.3 | 0.0 | (0.3) | 0.4 | 0.0 | 0.1 | 0.4 |
Mylan Balance Sheet
Annual
| USD | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|
Cash | 292.1m | 388.1m | 475.6m |
Accounts Receivable | 3.6b | 2.9b | 3.1b |
Prepaid Expenses | 766.1m | 518.4m | 552.0m |
Inventories | 2.5b | 2.6b | 2.7b |
Current Assets | 7.2b | 6.4b | 6.8b |
PP&E | 2.3b | 2.2b | 2.1b |
Goodwill | 10.2b | 9.7b | 9.6b |
Total Assets | 35.8b | 32.7b | 31.3b |
Accounts Payable | 1.5b | 1.6b | 1.5b |
Short-term debt | 1.9b | 701.7m | 1.5b |
Current Liabilities | 6.4b | 4.6b | 5.6b |
Long-term debt | 12.9b | 13.2b | 11.2b |
Total Debt | 14.7b | 13.9b | 12.7b |
Total Liabilities | 22.5b | 20.6b | 19.4b |
Common Stock | 6.0m | 6.0m | 6.1m |
Additional Paid-in Capital | 8.6b | 8.6b | 8.6b |
Retained Earnings | 5.6b | 6.0b | 6.0b |
Total Equity | 13.3b | 12.2b | 11.9b |
Debt to Equity Ratio | 1.1 x | 1.1 x | 1.1 x |
Debt to Assets Ratio | 0.4 x | 0.4 x | 0.4 x |
Financial Leverage | 2.7 x | 2.7 x | 2.6 x |
Quarterly
Mylan Cash Flow
Annual
| USD | FY, 2017 | FY, 2018 | FY, 2019 |
|---|---|---|---|
Net Income | 696.0m | 352.5m | 16.8m |
Depreciation and Amortization | 1.8b | 2.1b | 2.0b |
Accounts Receivable | (162.2m) | 340.1m | (20.0m) |
Inventories | (129.5m) | (547.6m) | (512.9m) |
Accounts Payable | 14.4m | 220.3m | (96.3m) |
Cash From Operating Activities | 2.1b | 2.3b | 1.8b |
Purchases of PP&E | (275.9m) | (252.1m) | (213.2m) |
Cash From Investing Activities | (905.4m) | (1.2b) | (525.4m) |
Short-term Borrowings | (2.9m) | (44.4m) | (1.8m) |
Long-term Borrowings | (2.2b) | (3.2b) | (1.1b) |
Cash From Financing Activities | (1.9b) | (1.1b) | (1.2b) |
Net Change in Cash | (706.7m) | 19.4m | 101.8m |
Interest Paid | 474.0m | 460.8m | 470.6m |
Income Taxes Paid | 285.7m | 228.6m | 278.6m |
Quarterly
Mylan Ratios
| USD | FY, 2017 |
|---|---|
EV/EBIT | 25.8 x |
EV/CFO | 18 x |
Revenue/Employee | 340.2k |
Debt/Equity | 1.1 x |
Debt/Assets | 0.4 x |
Financial Leverage | 2.7 x |
P/E Ratio | 32.5 |
Mylan Operating Metrics
| FY, 2017 | FY, 2018 | FY, 2019 | |
|---|---|---|---|
Products | 7.5 k | 7.5 k | 7.5 k |
Countries | 165 | 165 | 165 |
Products (Cardiovascular) | 1.15 k | 1.15 k | |
Products (Dermatology) | 500 | 500 | |
Products (Gastroenterology) | 700 | 700 | |
Products (Infectious Disease) | 1.1 k | 1.1 k | |
Products (Respiratory) | 600 | 600 | |
Products (Women's Health) | 650 | 650 | |
Products (Anesthesia) | 1.9 k | 1.9 k | |
Products (Diabetes & Metabolism) | 450 | 450 | |
Patents Issued | 4.5 k | 5 k | |
Products (Immunology) | 80 | 80 | |
Products (Oncology) | 450 | 450 | |
Products in Pipeline (Anesthesia) | 550 | 400 | |
Products in Pipeline (Cardiovascular Disease) | 320 | 300 | |
Products in Pipeline (Dermatology) | 60 | 60 | |
Products in Pipeline (Diabetes & Metabolism) | 300 | 250 | |
Products in Pipeline (Gastroenterology) | 150 | 100 | |
Products in Pipeline (Immunology) | 100 | 75 | |
Products in Pipeline (Infectious Disease) | 900 | 800 | |
Products in Pipeline (Oncology) | 550 | 500 | |
Products in Pipeline (Respiratory & Allergy) | 150 | 150 | |
Products in Pipeline (Women’s Health) | 150 | 150 | |
Research and Development Centers | 12 | 12 |
Mylan Sustainability Metrics
| FY, 2019 | |
|---|---|
Water Used (Rainwater) | 1 k cubic meters |
Water Used (Other) | 3 k cubic meters |
Water Used (On-Site Borewell) | 100 k cubic meters |
Water Used (Municipal) | 3.16 m cubic meters |
Water Recycled | 475 k cubic meters |
Water Discharged | 1.57 m cubic meters |
Water Consumed | 3.26 m cubic meters |
Waste Recycled, percent | 74% |
Waste Generated | 69 k tonnes |
Total Recordable Incident Rate | 0.67 |
Total Greenhouse Gas Emissions | 670 k tonnes |
Total Energy Used | 611 GWh |
Number of Fatalities | 0 |
Nonhazardous Waste Generated | 24 k tonnes |
Lost Time Incident Rate | 0.41 |
Hazardous Waste Generated | 45 k tonnes |
Greenhouse Gas Emissions Intensity | 58 tonnes per million USD revenue |
Greenhouse Gas Emissions (Scope 2) | 354 k tonnes |
Greenhouse Gas Emissions (Scope 1) | 316 k tonnes |
Energy Used from Renewable Energy Sources | 90 GWh |
Energy Used from Non-renewable Energy Sources | 521 GWh |
Energy Intensity Ratio | 0.05 GWh per million USD revenue |
Dart Rate | 0.47 |
Mylan Human Capital
Gender
| FY, 2018 | FY, 2017 | |
|---|---|---|
| Female, percent | 9.9% | 9.4% |
| Female (Management), percent | 8.9% | 8.7% |
| Male (Board), percent | 22.2% | 21.3% |
| Female (Board), percent | 11.1% | 12% |
| Male, percent | 23.4% | 23.9% |
| Male (Management), percent | 24.4% | 24.7% |
Job Roles
| FY, 2018 | FY, 2017 | |
|---|---|---|
| Scientific Affairs, percent | 8.2% | 8.6% |
| Management and Administration, percent | 13.7% | 13.7% |
| Sales and Marketing, percent | 21% | 19.7% |
| Operations, percent | 57.1% | 58% |
